News & AnalysisVaccitech rallies $168m Series BVaccitech, a clinical-stage biopharmaceutical company, has raised $168 million in Series B funding.ByIris Dorbian17 March 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs